

Scott Rodig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12085938/publications.pdf>

Version: 2024-02-01

28
papers

5,952
citations

218677

26
h-index

552781

26
g-index

28
all docs

28
docs citations

28
times ranked

12015
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors. , 2022, 10, e003569.		10
2	Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity. Cancer Discovery, 2021, 11, 1952-1969.	9.4	87
3	Inactivation of <i>Fbxw7</i> Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discovery, 2020, 10, 1296-1311.	9.4	49
4	Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nature Communications, 2020, 11, 1459.	12.8	176
5	Characterization of the Neuroendocrine Tumor Immune Microenvironment. Pancreas, 2018, 47, 1123-1129.	1.1	63
6	Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nature Medicine, 2018, 24, 1143-1150.	30.7	212
7	Anti-CTLA-4 based therapy elicits humoral immunity to galectin-3 in patients with metastatic melanoma. Oncoimmunology, 2018, 7, e1440930.	4.6	30
8	Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut, 2017, 66, 1463-1473.	12.1	173
9	Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology, 2017, 6, e1277308.	4.6	84
10	Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes. Cancer Immunology Research, 2017, 5, 446-454.	3.4	56
11	Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunology Research, 2017, 5, 480-492.	3.4	284
12	Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy. Cancer Immunology Research, 2017, 5, 17-28.	3.4	130
13	VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma. Cancer Immunology Research, 2016, 4, 858-868.	3.4	73
14	Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget, 2016, 7, 13587-13598.	1.8	485
15	Association of Polymerase ϵ -Mutated and Microsatellite-Unstable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncology, 2015, 1, 1319.	7.1	523
16	Immunological mechanisms of the antitumor effects of supplemental oxygenation. Science Translational Medicine, 2015, 7, 277ra30.	12.4	458
17	An Oncogenic Role for Alternative NF- κ B Signaling in DLBCL Revealed upon Deregulated BCL6 Expression. Cell Reports, 2015, 11, 715-726.	6.4	66
18	Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1 α -dependent and extracellular adenosine-mediated tumor protection. Journal of Molecular Medicine, 2014, 92, 1283-1292.	3.9	159

#	ARTICLE	IF	CITATIONS
19	Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma. <i>Cancer Immunology Research</i> , 2014, 2, 632-642.	3.4	512
20	Waldenström's Macroglobulinemia. , 2014, , 303-329.		0
21	Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy. <i>Clinical Cancer Research</i> , 2012, 18, 1611-1618.	7.0	582
22	Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. <i>Blood</i> , 2012, 119, 2579-2589.	1.4	544
23	The cell-cycle regulator c-Myc is essential for the formation and maintenance of germinal centers. <i>Nature Immunology</i> , 2012, 13, 1092-1100.	14.5	367
24	Antimyeloma Activity of a Multitargeted Kinase Inhibitor, AT9283, via Potent Aurora Kinase and STAT3 Inhibition Either Alone or in Combination with Lenalidomide. <i>Clinical Cancer Research</i> , 2011, 17, 3259-3271.	7.0	59
25	Constitutive Canonical NF- κ B Activation Cooperates with Disruption of BLIMP1 in the Pathogenesis of Activated B Cell-like Diffuse Large Cell Lymphoma. <i>Cancer Cell</i> , 2010, 18, 580-589.	16.8	177
26	Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2010, 16, 1033-1041.	7.0	112
27	Immunomodulatory Function of Bone Marrow-Derived Mesenchymal Stem Cells in Experimental Autoimmune Type 1 Diabetes. <i>Journal of Immunology</i> , 2009, 183, 993-1004.	0.8	355
28	Targeting CD22 Reprograms B-Cells and Reverses Autoimmune Diabetes. <i>Diabetes</i> , 2008, 57, 3013-3024.	0.6	126